Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03867617
PHASE1/PHASE2

Cell Therapy for Immunomodulation in Kidney Transplantation

Sponsor: Thomas Wekerle

View on ClinicalTrials.gov

Summary

This study investigates treatment with recipient regulatory T cells and donor bone marrow together with tocilizumab for immunomodulation in living donor kidney transplant recipients.

Official title: A Prospective Controlled Trial to Evaluate Safety and Efficacy of in Vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-mismatched Living Donor Kidney Transplant Recipients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2019-08-01

Completion Date

2028-06

Last Updated

2024-12-02

Healthy Volunteers

No

Interventions

OTHER

Regulatory T cells

Single infusion of expanded regulatory T cells.

DRUG

Tocilizumab

Treatment during first month post-transplant.

OTHER

Bone marrow

Infusion of donor bone marrow cells.

PROCEDURE

Kidney transplant

Living donor kidney transplantation.

OTHER

Immunosuppressive drug therapy

Immunosuppressive drug therapy.

Locations (1)

Medical University of Vienna/Vienna General Hospital

Vienna, Austria